GPI and arthritic joint disease: Taken together, entospletinib dose-dependently reduced the inflammatory signs of autoantibody-induced experimental arthritis without affecting the peripheral and the synovial numbers of critical cellular components under non-inflammatory conditions or the level of the pathogenic anti-GPI antibodies in the circulation after arthritis initiation.